JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Mirati Therapeutics Inc

Cerrado

SectorSanidad

0

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

Métricas clave

By Trading Economics

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-0.05% downside

Noticias sobre sentimiento de mercado

By Acuity

97%

3%

351 / 371 Clasificación en Healthcare

Mirati Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 oct 2025, 18:41 UTC

Ganancias

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 oct 2025, 18:31 UTC

Ganancias

Correction to Procter & Gamble to Focus on Innovation

24 oct 2025, 16:25 UTC

Principales Movimientos del Mercado

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 oct 2025, 21:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 oct 2025, 21:24 UTC

Charlas de Mercado

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 oct 2025, 21:07 UTC

Ganancias

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 oct 2025, 20:58 UTC

Ganancias

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 oct 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

24 oct 2025, 20:40 UTC

Ganancias

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 oct 2025, 20:24 UTC

Ganancias

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct 2025, 20:23 UTC

Ganancias

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct 2025, 20:13 UTC

Ganancias

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 20:07 UTC

Charlas de Mercado

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 oct 2025, 19:40 UTC

Charlas de Mercado

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 oct 2025, 19:35 UTC

Charlas de Mercado

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 oct 2025, 19:33 UTC

Ganancias

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 oct 2025, 19:29 UTC

Charlas de Mercado

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 oct 2025, 18:52 UTC

Ganancias

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct 2025, 18:41 UTC

Ganancias

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct 2025, 18:03 UTC

Ganancias

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 oct 2025, 18:02 UTC

Ganancias

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 oct 2025, 18:00 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 oct 2025, 16:57 UTC

Ganancias

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 oct 2025, 16:54 UTC

Charlas de Mercado

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 oct 2025, 16:44 UTC

Charlas de Mercado
Ganancias

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 oct 2025, 16:39 UTC

Charlas de Mercado
Ganancias

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 oct 2025, 16:33 UTC

Ganancias

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 16:23 UTC

Ganancias

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

24 oct 2025, 16:07 UTC

Ganancias

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Comparación entre iguales

Cambio de precio

Mirati Therapeutics Inc previsión

Precio Objetivo

By TipRanks

-0.05% descenso

Estimación a 12 Meses

Media 58.67 USD  -0.05%

Máximo 59 USD

Mínimo 58 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Mirati Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

0

Comprar

5

Mantener

0

Vender

Sentimiento

By Acuity

351 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

$

Acerca de Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
help-icon Live chat